Subgroup | Variant | Chr | Position | Allelesa | AAF | Unadjusted analyses | Adjusted analyses | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
HR [95% CI] | P value | BFDP | HR [95% CI] | P value | BFDP | ||||||
Grade 3 tumors | rs5934618b | X | 9437463 | A/G | 0.08 | 1.39 [1.24,1.56] | 1.7E-08 | 0.02 | 1.36 [1.21,1.53]e | 3.0E-07 | 0.17 |
rs4830644b | X | 9434808 | A/G | 0.08 | 1.39 [1.24,1.56] | 2.0E-08 | 0.02 | 1.35 [1.20,1.52]e | 4.8E-07 | 0.23 | |
rs3810742b, c | X | 9432603 | T/C | 0.08 | 1.38 [1.24,1.55] | 2.0E-08 | 0.02 | 1.35 [1.20,1.52]e | 4.2E-07 | 0.20 | |
rs4830642b | X | 9431786 | T/C | 0.08 | 1.38 [1.24,1.55] | 2.9E-08 | 0.02 | 1.35 [1.20,1.52]e | 5.8E-07 | 0.26 | |
rs72611496b | X | 9434264 | G/A | 0.08 | 1.38 [1.24,1.55] | 4.3E-08 | 0.03 | 1.34 [1.19,1.51]e | 1.2E-06 | 0.40 | |
rs66871326 | 2 | 209048052 | AAGGAG/A | 0.76 | 0.85 [0.80,0.90] | 2.1E-07 | 0.11 | 0.86 [0.81,0.92]e | 1.8E-06 | 0.49 | |
ER+ or PR+, and HER2- | rs8030394 | 15 | 71637241 | C/T | 0.99 | 2.47 [1.81,3.37] | 1.1E-08 | 0.42 | 2.38 [1.74,3.27]f | 7.6E-08 | 0.72 |
rs112641969 | 15 | 71715016 | A/G | 0.02 | 0.46 [0.35,0.61] | 4.6E-08 | 0.46 | 0.48 [0.36,0.64]f | 3.7E-07 | 0.78 | |
rs16955466 | 15 | 71637757 | C/T | 0.01 | 0.40 [0.29,0.55] | 1.5E-08 | 0.49 | 0.42 [0.31,0.58]f | 1.8E-07 | 0.82 | |
rs7165279 | 15 | 71636591 | T/C | 0.99 | 2.41 [1.77,3.28] | 2.7E-08 | 0.54 | 2.33 [1.70,3.19]f | 1.4E-07 | 0.78 | |
rs111962948 | 15 | 71656213 | G/T | 0.01 | 0.41 [0.29,0.56] | 3.0E-08 | 0.61 | 0.43 [0.31,0.60]f | 5.6E-07 | 0.91 | |
rs112813972 | 15 | 71577932 | T/C | 0.02 | 0.40 [0.28,0.55] | 4.0E-08 | 0.70 | 0.42 [0.30,0.59]f | 3.7E-07 | 0.90 | |
ER+ or PR+, and HER2- treated with CT | rs62192052 | 2 | 230372348 | C/T | 0.02 | 0.15 [0.08, 0.28] | 2.6E-09 | 0.99 | 0.15 [0.08, 0.29]g | 5.5E-09 | 0.99 |
rs74423556c | 2 | 230325234 | C/G | 0.02 | 0.16 [0.08,0.30] | 2.1E-08 | 0.99 | 0.16 [0.08,0.31]g | 3.8E-08 | 1.00 | |
rs145983608 | 2 | 230296944 | A/G | 0.02 | 0.15 [0.08,0.30] | 3.8E-08 | 1.00 | 0.15 [0.08,0.31]g | 1.1E-07 | 1.00 | |
ER+ or PR+, and HER2- not treated with CT | rs56248395b | 11 | 20084391 | C/T | 0.13 | 2.33 [1.72,3.15] | 4.8E-08 | 0.59 | 2.23 [1.66,2.99]g | 1.2E-07 | 0.69 |
ER+ treated with ET | rs4679741 | 3 | 155003603 | T/G | 0.49 | 1.18 [1.11,1.26] | 1.6E-07 | 0.09 | 1.20 [1.13,1.28] h | 1.1E-08 | 0.01 |
ER- treated with CT | rs78754389d | 4 | 35962454 | G/A | 0.07 | 1.79 [1.46,2.20] | 1.7E-08 | 0.07 | 1.67 [1.39,2.00] i | 4.1E-08 | 0.09 |
rs1106333 | 3 | 14562127 | C/A | 0.06 | 1.68 [1.39,2.03] | 5.6E-08 | 0.12 | 1.70 [1.41,2.05] i | 4.4E-08 | 0.11 | |
rs117685664d | 8 | 26989084 | C/T | 0.03 | 0.26 [0.16,0.42] | 4.6E-08 | 0.97 | 0.50 [0.35,0.70]i | 6.4E-05 | 0.99 | |
Tamoxifen | rs72775397d | 5 | 94266932 | C/T | 0.28 | 1.36 [1.21,1.53] | 1.8E-07 | 0.11 | 1.11 [1.03,1.19]j | 6.6E-03 | 1.00 |
Anthracylines | rs34072391 | 7 | 30243729 | C/CA | 0.52 | 1.27 [1.17,1.39] | 6.2E-08 | 0.04 | 1.26 [1.15,1.37]k | 3.4E-07 | 0.16 |